AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+7.02%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$5.38B
AUM Growth
+$5.38B
(+6.7%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
0.22%
Top 10 Holdings %
Top 10 Hldgs %
92.84%
Holding
124
New
16
Increased
27
Reduced
16
Closed
13
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$25.4M |
| 2 |
Incyte
INCY
|
$9.47M |
| 3 |
argenx
ARGX
|
$9.2M |
| 4 |
AXDX
Accelerate Diagnostics
AXDX
|
$7.86M |
| 5 |
Denali Therapeutics
DNLI
|
$7.82M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$50.8M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$18.6M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$12.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$11.6M |
| 5 |
RXDX
Ignyta, Inc.
RXDX
|
$11.1M |
Sector Composition
| 1 | Consumer Staples | 53.33% |
| 2 | Consumer Discretionary | 24.25% |
| 3 | Healthcare | 21.69% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ironwood Pharmaceuticals
IRWD
$195M
| $7.75M | 0.12% |
516,879
-300,000
| -37% | -$4.5M |
|
|
ALBO
27
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $7.68M | 0.12% |
+300,000
| New | +$7.68M |
|
|
BPMC
28
DELISTED
Blueprint Medicines
BPMC
| $7.54M | 0.11% |
+100,000
| New | +$7.54M |
|
|
PTLA
29
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.3M | 0.11% |
+150,000
| New | +$7.3M |
|
|
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.8M | 0.1% |
100,000
-15,000
| -13% | -$1.02M |
|
31
AC Immune
ACIU
$228M
| $6.4M | 0.1% |
500,000
| – | – |
|
|
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
| $6.25M | 0.09% |
200,000
| – | – |
|
33
ProQR Therapeutics
PRQR
$253M
| $6.13M | 0.09% |
1,900,000
+400,000
| +27% | +$1.29M |
|
|
ALDR
34
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $5.73M | 0.09% |
500,000
| – | – |
|
|
MDCO
35
DELISTED
Medicines Co
MDCO
| $5.47M | 0.08% |
200,000
-100,000
| -33% | -$2.73M |
|
36
Synlogic
SYBX
$17.2M
| $5.34M | 0.08% |
+550,000
| New | +$5.34M |
|
37
Immunic
IMUX
$76.9M
| $5.21M | 0.08% |
875,000
| – | – |
|
38
Puma Biotechnology
PBYI
$261M
| $4.94M | 0.07% |
+50,000
| New | +$4.94M |
|
39
Intellia Therapeutics
NTLA
$1.24B
| $4.81M | 0.07% |
250,000
+75,000
| +43% | +$1.44M |
|
|
ADAP
40
Adaptimmune Therapeutics
ADAP
$14.6M
| $4.68M | 0.07% |
700,000
+200,000
| +40% | +$1.34M |
|
41
Larimar Therapeutics
LRMR
$330M
| $4.62M | 0.07% |
1,000,000
| – | – |
|
|
JUNO
42
DELISTED
Juno Therapeutics, Inc.
JUNO
| $4.57M | 0.07% |
100,000
-50,000
| -33% | -$2.29M |
|
|
CBIO
43
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $4.2M | 0.06% |
250,000
+47,500
| +23% | +$798K |
|
44
Spero Therapeutics
SPRO
$116M
| $4.11M | 0.06% |
+350,000
| New | +$4.11M |
|
45
Dynavax Technologies
DVAX
$1.18B
| $3.74M | 0.06% |
200,000
+50,000
| +33% | +$935K |
|
46
Lineage Cell Therapeutics
LCTX
$279M
| $3.35M | 0.05% |
1,557,050
+275,000
| +21% | +$591K |
|
47
TG Therapeutics
TGTX
$4.97B
| $3.28M | 0.05% |
400,000
| – | – |
|
48
Wave Life Sciences
WVE
$1.25B
| $3.23M | 0.05% |
+92,078
| New | +$3.23M |
|
|
STML
49
DELISTED
Stemline Therapeutics, Inc.
STML
| $3.12M | 0.05% |
200,000
-50,000
| -20% | -$780K |
|
50
Verastem
VSTM
$568M
| $3.07M | 0.05% |
1,000,000
+250,000
| +33% | +$767K |
|